DeFloria announced Thursday that its experimental cannabis-based drug for autism spectrum disorder showed positive early results, with patients tolerating the treatment well across multiple dose levels. The drug, AJA001, being developed as a multi-compound hemp extract with a full spectrum of cannabinoids, demonstrated safety at daily doses up to 660 …
![](https://i0.wp.com/extroverting.com/wp-content/uploads/CBD-2-scaled-1.jpg?fit=640%2C427&ssl=1)